-
-
Can CRISPR Deliver?A gene-editing tool called CRISPR holds promise for treating cancer. What does the new technology mean for patients?
by Stephen Ornes
-
The Puzzle of Pancreatic CancerPancreatic cancer remains a difficult disease to treat and is expected to be the second leading cause of U.S. cancer-related deaths by 2030. Researchers hope clinical trials and insights into the genetics of the disease will reverse the trend.
by Kendall K. Morgan
-
The Coronavirus Impacts Cancer Clinical TrialsThe National Cancer Institute and the Food and Drug Administration have provided guidance for managing clinical trials amid the spread of the novel coronavirus. Cancer centers are making changes to care for some patients enrolled in trials.
by Anna Azvolinsky
-
Policy Matters
Taking Steps to Address Cancer Health DisparitiesCancer outcomes are changing for the better, but advances are not affecting all patients equally.
by Brian Rivers, PhD
-
The Coronavirus and Cancer CareCancer patients in the U.S. are feeling impacts from the new coronavirus.
by Kate Yandell
-
Medicare Coverage for Next-Generation Sequencing TestsMultigene panels that rely on next-generation sequencing are increasingly used to test for hereditary cancer risk-related mutations. The federal government aims to expand Medicare coverage for these tests.
by Ashley P. Taylor
-
For Prostate Biopsy, It’s Best to Combine Old and New MethodsUsing an older method of prostate biopsy together with MRI-targeted biopsy more accurately diagnoses prostate cancer than either method alone, a study finds.
by Kate Yandell
-
Drinking After a DiagnosisA study illuminates the alcohol consumption habits of cancer survivors.
by Jen Tota McGivney
-
New Drugs for an Elusive Cancer TargetMedical oncologist and lung cancer expert Roy S. Herbst discusses early data on drugs that target a mutated form of the KRAS protein.
by Anna Azvolinsky
U.S. breast cancer deaths declined for women ages 20 to 49, which researchers credit to wider screening and better treatment.
by Kevin McLaughlin
Missed Activities Due to Cancer-related Fatigue and DepressionWomen were more likely than men to have fatigue or depression linked to cancer, and both effects were linked to people withdrawing from physical activities.
by Eric Fitzsimmons
Immunotherapy Improves Results in Head and Neck CancerCombining an immune checkpoint inhibitor with standard care extended event-free survival by nearly two years.
by Thomas Celona
Federal Support for Cancer Research Takes the Stage at AACR Annual MeetingScientists and former administrators gather for session focused on advocating for cancer research in uncertain times.
by Kevin McLaughlin
-
Inaugural AACR IO Conference Kicks Off With Celebration of Immune CheckpointsImmune checkpoint icons James Allison and Arlene Sharpe shared their journeys and a look ahead on the opening night of the inaugural AACR IO conference.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
